Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Bayer extends KERENDIA development with study in use as CKD treatment » 08:16
09/20/21
09/20
08:16
09/20/21
08:16
BAYRY

Bayer

$13.29 /

-0.19 (-1.41%)

Bayer announced the…

Bayer announced the initiation of the FIND-CKD study, for an investigational new use of KERENDIA, finerenone, in addition to guideline-directed therapy, on the progression of chronic kidney disease in patients with nondiabetic CKD. The primary objective of the study is to demonstrate superiority of finerenone over placebo in delaying the progression of CKD in these patients. The primary outcome measure is the mean rate of change in kidney function over time, estimated glomerular filtration rate from baseline to month 32. "In 2017, an alarming 1.2M people died from chronic kidney disease worldwide. Although diabetes is well-recognized as a leading cause of chronic kidney disease globally, a substantial proportion of the global burden is nondiabetic in origin and attributable to other causes, such as hypertension.To improve outcomes, there is an urgent need for new treatments,"said Hiddo L. Heerspink, professor of clinical trials and personalized medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, Netherlands, and co-chair of the study's executive committee. "If successful, this study could be of great significance to those living with chronic kidney disease globally."

ShowHide Related Items >><<
BAYRY Bayer
$13.29 /

-0.19 (-1.41%)

BAYRY Bayer
$13.29 /

-0.19 (-1.41%)

08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
BAYRY Bayer
$13.29 /

-0.19 (-1.41%)

BAYRY Bayer
$13.29 /

-0.19 (-1.41%)

BAYRY Bayer
$13.29 /

-0.19 (-1.41%)

Over a week ago
Hot Stocks
BWX Technologies, Bayer partner to develop Actinium-225 » 06:49
09/16/21
09/16
06:49
09/16/21
06:49
BWXT

BWX Technologies

$54.73 /

+0.05 (+0.09%)

, BAYRY

Bayer

$13.46 /

-0.02 (-0.15%)

BWX Technologies (BWXT)…

BWX Technologies (BWXT) announced that its BWXT Medical Ltd. subsidiary has entered into an agreement with Bayer AG (BAYRY) to develop Actinium-225 supply and further partnering opportunities on finished products as both companies broaden their respective commercialization strategies for targeted radionuclide therapies and other innovative products. Ac-225 is a highly powerful radioisotope used in targeted alpha therapies, an emerging class of radionuclide therapy for various tumors with a high unmet medical need, delivering alpha radiation directly to tumors either via its bone-seeking properties or by combining alpha radionuclides such as Ac-225 with specific tumor-seeking targeting vectors. BWXT Medical plans to utilize its deep relationships with strategic partners in irradiation services and development of Ac-225. Much like BWXT Medical's other products, processing and manufacturing would then be conducted at BWXT Medical facilities. Bayer and BWXT Medical have structured the evolution of their relationship to progress over stages, and the complete terms of the commercial agreements will be finalized at a later date.

ShowHide Related Items >><<
BWXT BWX Technologies
$54.73 /

+0.05 (+0.09%)

BAYRY Bayer
$13.46 /

-0.02 (-0.15%)

BWXT BWX Technologies
$54.73 /

+0.05 (+0.09%)

06/23/21 Credit Suisse
BWX Technologies downgraded to Neutral from Outperform at Credit Suisse
04/08/21 Maxim
BWX Technologies price target raised to $80 from $75 at Maxim
01/07/21 Baird
BWX Technologies downgraded to Neutral from Outperform at Baird
10/15/20 BofA
BWX Technologies upgraded to Buy from Neutral at BofA
BAYRY Bayer
$13.46 /

-0.02 (-0.15%)

08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
BWXT BWX Technologies
$54.73 /

+0.05 (+0.09%)

BAYRY Bayer
$13.46 /

-0.02 (-0.15%)

BAYRY Bayer
$13.46 /

-0.02 (-0.15%)

BAYRY Bayer
$13.46 /

-0.02 (-0.15%)

Over a month ago
Hot Stocks
Bayer files petition to U.S. Supreme Court for review of Hardeman decision » 10:30
08/16/21
08/16
10:30
08/16/21
10:30
BAYRY

Bayer

$14.14 /

+0.0175 (+0.12%)

Bayer - through its…

Bayer - through its subsidiary Monsanto - filed its Petition for a Writ of Certiorari with the U.S. Supreme Court in Hardeman, which it calls "the only Roundup federal product liability case to have gone to trial." The petition urges the court to review the Ninth Circuit Court of Appeals' decision on two grounds. "First, the state-law failure-to-warn claims at the center of the case are preempted by federal law, as the U.S. Government argued in its amicus filing in the Ninth Circuit. Second, the admission of expert testimony departed from federal standards, enabling plaintiff's causation witnesses to provide unsupported testimony on the principal issue in the case, Roundup's safety profile," the company stated. Reference Link

ShowHide Related Items >><<
BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

Hot Stocks
111 and Bayer Healthcare expand strategic partnership » 08:15
08/16/21
08/16
08:15
08/16/21
08:15
YI

111, Inc.

$5.89 /

-0.08 (-1.34%)

, BAYRY

Bayer

$14.14 /

+0.0175 (+0.12%)

111 announced the…

111 announced the expansion of its existing partnership with Bayer Healthcare. 111 and Bayer Healthcare first entered into a strategic partnership in September 2020, to collaborate on drug commercialization initiatives in China. Specifically, 111 and Bayer agreed to work towards the commercialization of innovative drugs and healthcare products for chronic disease management, as well as providing useful resources for patient education. Leveraging 111's vast network of pharmacies and healthcare providers facilitates the expansion of Bayer's presence in underserved markets in China, as well as enhances the leading drug maker's channel management and patient outreach capabilities. The two companies also agreed to jointly develop a digital content portal that provides online pharmacist training, as well as interactive patient education, and other services.

ShowHide Related Items >><<
YI 111, Inc.
$5.89 /

-0.08 (-1.34%)

BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

YI 111, Inc.
$5.89 /

-0.08 (-1.34%)

04/15/21 Citi
111, Inc. transferred with Buy rating, $16 target at Citi
BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

BAYRY Bayer
$14.14 /

+0.0175 (+0.12%)

Hot Stocks
Berkeley Lights announces multi-year agreement with Bayer » 06:05
08/11/21
08/11
06:05
08/11/21
06:05
BLI

Berkeley Lights

$43.77 /

-0.93 (-2.08%)

, BAYRY

Bayer

$13.89 /

+0.04 (+0.29%)

Berkeley Lights (BLI)…

Berkeley Lights (BLI) announced a multi-year agreement with Bayer (BAYRY) to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits. Terms of the agreement were not disclosed. Berkeley Lights will leverage its platform to screen individual variants of bioactives for Bayer in a massively high-throughput manner. The outcome will be a significant acceleration of the agricultural leader's pipeline for discovery and development of novel traits. This agreement marks the first application of Berkeley Lights' technology for use in the agricultural sector.

ShowHide Related Items >><<
BLI Berkeley Lights
$43.77 /

-0.93 (-2.08%)

BAYRY Bayer
$13.89 /

+0.04 (+0.29%)

BLI Berkeley Lights
$43.77 /

-0.93 (-2.08%)

06/28/21 KeyBanc
Berkeley Lights downgraded to Sector Weight from Overweight at KeyBanc
06/22/21 BTIG
Berkeley Lights initiated with a Buy at BTIG
01/27/21
Fly Intel: Top five analyst initiations
01/27/21 Stifel
Stifel starts Berkeley Lights at Buy with $105 price target
BAYRY Bayer
$13.89 /

+0.04 (+0.29%)

08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
BLI Berkeley Lights
$43.77 /

-0.93 (-2.08%)

BAYRY Bayer
$13.89 /

+0.04 (+0.29%)

  • 19
    Nov
BLI Berkeley Lights
$43.77 /

-0.93 (-2.08%)

BAYRY Bayer
$13.89 /

+0.04 (+0.29%)

BLI Berkeley Lights
$43.77 /

-0.93 (-2.08%)

BAYRY Bayer
$13.89 /

+0.04 (+0.29%)

Periodicals
Bayer loses third straight Roundup verdict appeal, Bloomberg says » 16:27
08/09/21
08/09
16:27
08/09/21
16:27
BAYRY

Bayer

$13.85 /

+0.01 (+0.07%)

A California appeals…

A California appeals court refused to overturn a 2019 verdict against Bayer and its Roundup herbicide, handing the company a third consecutive appeals court loss in cases that have gone to trial over the product, though the appeals court left intact the trial judge's decision to reduce the award to $86.7M from a prior jury award of more than $2B, reported Bloomberg Law. Reference Link

ShowHide Related Items >><<
BAYRY Bayer
$13.85 /

+0.01 (+0.07%)

BAYRY Bayer
$13.85 /

+0.01 (+0.07%)

08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
BAYRY Bayer
$13.85 /

+0.01 (+0.07%)

BAYRY Bayer
$13.85 /

+0.01 (+0.07%)

BAYRY Bayer
$13.85 /

+0.01 (+0.07%)

Periodicals
Bayer loses another appeal of Roundup case, Bloomberg says » 15:59
08/09/21
08/09
15:59
08/09/21
15:59
BAYRY

Bayer

$13.84 /

+0.032 (+0.23%)

Bayer has lost an appeal…

Bayer has lost an appeal in a third straight Roundup lawsuit, according to Bloomberg.

ShowHide Related Items >><<
BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

08/09/21 Berenberg
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

Recommendations
Bayer price target lowered to EUR 60 from EUR 74 at Berenberg » 14:06
08/09/21
08/09
14:06
08/09/21
14:06
BAYRY

Bayer

$13.84 /

+0.032 (+0.23%)

Berenberg analyst…

Berenberg analyst Sebastian Bray lowered the firm's price target on Bayer to EUR 60 from EUR 74 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
05/19/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

BAYRY Bayer
$13.84 /

+0.032 (+0.23%)

Recommendations
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse » 13:51
08/06/21
08/06
13:51
08/06/21
13:51
BAYRY

Bayer

$13.81 /

-0.992 (-6.70%)

Credit Suisse analyst…

Credit Suisse analyst Johanna Walton lowered the firm's price target on Bayer to EUR 55 from EUR 60 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

08/06/21 Credit Suisse
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse
08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
05/19/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
05/19/21 JPMorgan
JPMorgan upgrades Bayer to Overweight with earnings at 'turning point'
BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

Recommendations
Bayer price target lowered to EUR 55 from EUR 60 at Credit Suisse » 13:51
08/06/21
08/06
13:51
08/06/21
13:51
BAYRY

Bayer

$13.81 /

-0.992 (-6.70%)

Credit Suisse analyst…

Credit Suisse analyst Johanna Walton lowered the firm's price target on Bayer to EUR 55 from EUR 60 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

08/04/21 AlphaValue/Baader
Bayer downgraded to Add from Buy at AlphaValue
05/19/21 Morgan Stanley
Bayer price target raised to EUR 71 from EUR 70 at Morgan Stanley
05/19/21 JPMorgan
JPMorgan upgrades Bayer to Overweight with earnings at 'turning point'
05/18/21 JPMorgan
Bayer upgraded to Overweight from Neutral at JPMorgan
BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

BAYRY Bayer
$13.81 /

-0.992 (-6.70%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.